What are the advantages of giltinib in maintenance therapy?

Gilteritinib can significantly improve the survival rate of patients with FLT3 mutation-positive leukemia. Studies have shown that the median overall survival of patients treated with giltinib is significantly improved compared with the control group. For example, in a pivotal clinical trial, patients treated with giltinib had a median overall survival of 9.3 months, compared with only 5.6 months in the control group. This data fully demonstrates the significant effect of giltinib in maintenance therapy.

In addition to improving survival rates, giltinib can effectively extend patients' progression-free survival. This means that patients' condition can remain stable for a longer period of time after receiving giltinib treatment, reducing the risk of recurrence.

Giltinib treatment reduces the risk of death by approximately36%. This data shows that giltinib can not only effectively control the disease in the short term, but also significantly reduce the patient's risk of death during long-term maintenance treatment.

In clinical trials, giltinib demonstrated good safety and tolerability. Although patients may experience some adverse reactions, such as fatigue, nausea, etc., these reactions are generally expected and can be controlled with appropriate medical management. Overall, giltinib has relatively few side effects, allowing patients to continue receiving treatment and maintain a good quality of life.

Giltinib can not only be used as a single treatment drug, but can also be used in combination with other drugs, such as chemotherapy drugs, hypomethylating drugs, etc. This combined treatment regimen may achieve better efficacy and provide patients with more treatment options.